Evidence map›Paper›PMID 35607596›Full record

ArticleDrug design, development and therapy2022

Effects of Ethanolic Extract of

Qing Sun, Li Li, Quan Zhou

Open access · goldAbstract read
In one paragraph

Article in Drug design, development and therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Qing SunDepartment of Pharmacy, Zhejiang Hospital, Hangzhou, People's Republic of China.
Li LiDepartment of Pharmacy, Zhejiang Hospital, Hangzhou, People's Republic of China.
Quan ZhouDepartment of Pharmacy, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, People's Republic of China.
Zhejiang Hospital · CNSecond Affiliated Hospital of Zhejiang University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Wuzhi capsule (WZ) is a proprietary Chinese medicine prepared from the ethanolic extract of Methods: Eighteen male rats were randomly and evenly divided into three groups: control group (gavage feeding of rosuvastatin 10 mg·kg Results: In both male and female rats, there were no statistically significant differences in rosuvastatin pharmacokinetic parameters between the control group, the single dose group, and the multi-dose group. Conclusion: Acute or long-term intake of WZ had no obvious effect on the pharmacokinetics of rosuvastatin, and therefore rosuvastatin could be used as an alternative to atorvastatin and simvastatin when WZ is clinically required in conjunction with statins. An appropriate pharmacodynamic study is needed to encourage the safe use of this combination.

Indexed as

Diabetes Mellitus, Type 2Hydroxymethylglutaryl-CoA Reductase InhibitorsSchisandraAnimalsAtorvastatinChromatography, LiquidFemaleHumansMaleRatsRats, Sprague-DawleyRosuvastatin CalciumSimvastatinTandem Mass SpectrometryAtorvastatinHydroxymethylglutaryl-CoA Reductase InhibitorsRosuvastatin CalciumSimvastatinherb-drug interactionhyperlipidemiametabolic syndromepharmacokineticsrosuvastatinWuzhi capsule

Identifiers

PMID35607596
PMCPMC9123906
OpenAlexW4280631314

What OpenQuestion holds

Texttitle and abstract
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.